Non-small-cell lung cancer (NSCLC) is the most common type of cancer affecting the lungs. The diverse types of NSCLC are characterized by cancer cells that grow and spread in different ways.

Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address ...

Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some ...

Opdivo (nivolumab) is a brand-name IV infusion prescribed for non-small cell lung cancer (NSCLC) in some situations. This article covers topics such as side effects, dosage, and how Opdivo works.

Researchers have shown that activation of the protein YAP, known to help cancer cells survive treatment, behaves very differently in cell culture models depending on how they are grown in the lab, ...

Patients in the ivonescimab group demonstrated a significantly greater progression-free survival than those in the ...

locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in patients whose disease has progressed despite earlier treatment with tyrosine kinase inhibitors (TKIs) and ...

"Optune Lua is an innovative and urgently needed new approach for treating metastatic non-small cell lung cancer," said Joachim Aerts, M.D., a LUNAR investigator and Professor of Pulmonary ...

Key exclusion criteria included a history of severe immune-related adverse events from prior immune checkpoint inhibitor use, untreated or symptomatic central nervous system metastases, and a history ...